EURETINA 2025: Dr. Awh Contributes to Global Conversations on Retinal Care
Tennessee Retina at EURETINA 2025
This past week, our very own Dr. Carl C. Awh attended the 25th EURETINA Congress in Paris, France, one of the world’s premier meetings for retinal specialists. He was able to contribute his expertise and insights in several key sessions.
Advancing Retinal Care: Contivue® with Susvimo
Dr. Awh served as a study investigator presenting new long-term data on Roche’s Port Delivery Platform, now known in the EU as Contivue® with Susvimo. This innovative sustained delivery implant is designed to provide continuous treatment for patients with neovascular age-related macular degeneration (nAMD), potentially reducing the need for frequent intravitreal injections.
The seven-year data from the LADDER study, presented at EURETINA, showed that Contivue with Susvimo maintained good vision and stable retinal anatomy over time. Dr. Awh highlighted the potential of this treatment to deliver more durable outcomes and improve long-term quality of life for patients.
For patients with nAMD, the sustained drug delivery of Contivue with Susvimo may provide superior visual outcomes compared to the well-demonstrated average decline in vision associated with long-term intravitreal injections.— Dr. Awh
Sharing Expertise on Global Panels
In addition to his research contributions, Dr. Awh also participated in two important sessions at EURETINA:
- Roche Symposium: Through Our Patients’ Eyes – Patient Voices in the Era of Continuous Drug Delivery for Retinal Disease
- Amgen Panel: Decoding Biosimilars and Biosimilar Development
These sessions provided opportunities to discuss both innovative treatment delivery systems and the evolving role of biosimilars in retinal care.
Commitment to the Future of Ophthalmology
Dr. Awh’s involvement at EURETINA highlights how Tennessee Retina physicians are helping shape the conversation around the future of retinal treatments. His work on the global stage demonstrates our practice’s dedication not only to caring for patients here at home but also to advancing innovations that may change the way vision-threatening diseases are treated worldwide.
Read more about this topic HERE
